Estrogen receptor protein in lesions of the male breast.A preliminary report
- 1 April 1976
- Vol. 37 (4), 1866-1868
- https://doi.org/10.1002/1097-0142(197604)37:4<1866::aid-cncr2820370434>3.0.co;2-1
Abstract
Eleven specimens of breast lesions obtained from 10 male patients were analyzed for estrogen receptor protein (ERP). Three patients (ages 49, 77, 82 years) had infiltrating duct carcinomas with no axillary metastases. ERP in each of these was positive. Eight specimens with gynecomastia, one of which was obtained from the 77-year-old patient with carcinoma in the same breast, were also analyzed. Of these ERP was positive in a 59-year-old man who had cirrhosis of the liver; two patients with borderline ERP had hepatitis and testicular seminoma, respectively. No relationship between histopathologic features of the lesions and ERP results was found and it is too early to relate these ERP studies to prognosis in these patients. Review of available literature, including our cases, reveals that six of eight male breast carcinomas were ERP-positive.This publication has 4 references indexed in Scilit:
- Malignant and benign human mammary disease: Estrogen binding in relation to clinical dataCancer, 1974
- Hormone dependence in breast cancerMetabolism, 1974
- The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgey (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (estrogens and corticosteroids).An analysis of 42 patientsCancer, 1959
- Gynecomastia during Digitalis TherapyNew England Journal of Medicine, 1953